Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer

  • Gary Onik
  • Boris Rubinsky
Part of the Series in Biomedical Engineering book series (BIOMENG)

Abstract

Irreversible electroporation (IRE) is a new non-thermal ablation modality that uses short pulses of DC electric current to create irreversible pores in the cell membrane thus causing cell death. This method has been shown by Rubinsky et al. to have significant advantages in ablating prostatic tissue, such as rapid lesion creation, rapid lesion resolution, sparing of structures such as vessels, nerves and urethra, and uniform destruction throughout the IRE lesion (1). The underlying principles are well covered in other chapters in this book. This discussion will deal with the first human applications of IRE and whether its theoretical promises of improved clinical outcomes, have been delivered. For a number of reasons, including the ability to carry out extensive post operative biopsies to confirm the adequate ablation of cancer, the first human experience was carried out in the prostate.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rubinsky, B., Onik, G., Mikus, P.: Irreversible electroporation: a new ablation modality–clinical implications. Technol. Cancer Res. Treat. 6(1), 37–48 (2007)Google Scholar
  2. 2.
    Onik, G., Narayan, P., Vaughan, D., et al.: Focal nerve sparing cryoablation for the treatment of primary prostate cancer: A new approach to preserving potency. Urology 60(1), 109–114 (2002)CrossRefGoogle Scholar
  3. 3.
    Onik, G., Vaughan, D., Lotenfoe, R., Dineen, M., Brady, J.: Male lumpectomy: focal therapy for prostate cancer using cryoablation. Urology 70(suppl. 6), 16–21 (2007)CrossRefGoogle Scholar
  4. 4.
    Bahn, D.K., Silverman, P., Lee, F., Badalament, R., Bahn, E.D., Rewcastle, J.C.: Focal prostate cryoablation: initial results show cancer control and potency preservation. J. Endourol. 20(9), 688–692 (2006)CrossRefGoogle Scholar
  5. 5.
    Lambert, E.H., Bolte, K., Masson, P., Katz, A.E.: Focal cryosurgery: encouraging health outcomes for uni-focal prostate cancer. Urology 69(6), 1117–1120 (2007)CrossRefGoogle Scholar
  6. 6.
    Bahn, D.K., Lee, F., Bandalament, R., et al.: 7-year outcomes in the primary treatment of prostate cancer. Urology 60(suppl. 1, 2), 3–11 (2002)CrossRefGoogle Scholar
  7. 7.
    Bostwick, D.G., Waters, D.J., Farley, E.R., Meiers, I., Rukstalis, D., Cavanaugh, W.A., Ragde, H., Dineen, M.K., Bahn, D., Scionti, S., Babian, R., Ellis, D.S., Rewcastle, J.C., Burke, H.B., Andriole, G.L., Onik, G., Barqawi, A.E., Maksem, J., Barzell, W.E.: Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida (February 24, 2006); Urology 70(suppl. 6), 42–44 (December 2007)Google Scholar
  8. 8.
    Santiago, R.J., Wu, L., Harris, E., Fox, K., Schultz, D., Glick, J., Solin, L.J.: Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 233–240 (2004)CrossRefGoogle Scholar
  9. 9.
    Messing, E.M., Thompson, I.: Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol. Clin. North Am. 30(4), 687–702 (2003)CrossRefGoogle Scholar
  10. 10.
    Djvan, B., Susani, M., Bursa, B., et al.: Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Techniques in Urology 5(3), 139–142 (1999)Google Scholar
  11. 11.
    Villars, A., McNeal, J.E., Freiha, F.S., et al.: Multiple cancers in the prostate. Morphological features of clinically recognized vs. incidental tumors. Urology 60(2A), 19–25 (2002)CrossRefGoogle Scholar
  12. 12.
    Noguchi, M., Stamey, T.A., McNeal, J.E., et al.: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary tumors. J. Uril. 170(2pt), 459–463 (2003)CrossRefGoogle Scholar
  13. 13.
    Rukstalis, D.B., Goldknopf, J.L., Crowley, E.M., et al.: Prostate cryoablation: A scientific rationale for future modifications. Urology 60(2A), 19–25 (2002)CrossRefGoogle Scholar
  14. 14.
    Crawford, E.D., Wilson, S.S., Torkko, K.C., et al.: Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int. 96(7), 999–1004 (2005)CrossRefGoogle Scholar
  15. 15.
    Gary Onik, M.D., Winston Barzell, M.D.: Transperineal 3D Mapping Biopsy of the Prostate: An Essential Tool in Selecting Patients for Focal Prostate Cancer Therapy. Urologic Oncology: Seminars and Original Investigations (in Press)Google Scholar
  16. 16.
    Barzell, W.E., Melamed, M.R.: Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology 70(suppl. 6), 27–35 (2007)CrossRefGoogle Scholar
  17. 17.
    Health Care Financing Administration. Medicare Coverage Policy: Decisions. Bagley GP. Cryosurgery ablation of the prostate (#CAG-00031), http://www.hcfa.gov/coverage/8b3-f1.htm (accessed November 7, 2001)
  18. 18.
    Donnelly, B.J., Saliken, J.C., Brasher, P., et al.: Randomized controlled trial comparing external beam radiation and cryoablation in localized prostate cancer. In: Proceedings of the American Urological Association of 2007 (2007), Abstract #1141Google Scholar
  19. 19.
    Eggener, S.E., Scardino, P.T., Carroll, P.R., Zelefsky, M.J., Sartor, O., Hricak, H., Wheeler, T.M., Fine, S.W., Trachtenberg, J., Rubin, M.A., Ohori, M., Kuroiwa, K., Rossignol, M., Abenhaim, L.: International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J. Urol. 178(6), 2260–2267 (2007) (Epub October 15, 2007)CrossRefGoogle Scholar
  20. 20.
    Ahmed, H.U., Pendse, D., Illing, R., Allen, C., van der Meulen, J.H., Emberton, M.: Will focal therapy become a standard of care for men with localized prostate cancer? Nat. Clin. Pract. Oncol. 4(11), 632–642 (2007)CrossRefGoogle Scholar
  21. 21.
    Mouraviev, V., Mayes, J.M., Sun, L., Madden, J.F., Moul, J.W., Polascik, T.J.: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110(4), 906–910 (2007)CrossRefGoogle Scholar
  22. 22.
    Neumann, E., Schaefer-Ridder, M., Wang, Y., Hofschneider, P.H., et al.: Gene transfer into mouse lyoma cells by electroporation in high electric fields. J. EMBO 1, 841–845 (1982)Google Scholar
  23. 23.
    Mir, L.M., Belehradek, M., Domenge, C., Luboniski, B., Orlowski, S., Belehradek, J., Schwaab, B., Luboniski, B., Paoletti, C.: Electrochemotherapy, a novel antitumor treatment: first clinical trial. C. R. Acad. Sci. Ser. III 313, 613–618 (1991)Google Scholar
  24. 24.
    Davalos, R.V., Mir, L.M., Rubinsky, B.: Tissue ablation with irreversible electroporation. Annals of Biomedical Engineering 33(2), 223–231 (2005)CrossRefGoogle Scholar
  25. 25.
    Onik, G., Mikus, P., Rubinsky, B.: Irreversible electroporation: implications for prostate ablation. Technol. Cancer Res. Treat. 6(4), 295–300 (2007)Google Scholar
  26. 26.
    Miller, L., Leor, J., Rubinsky, B.: Cancer cells ablation with irreversible electroporation. Technology in Cancer Research and Treatment 4(6), 1–6 (2005)Google Scholar
  27. 27.
    Ellis, D., Jones, J., Pisters, L., et al.: Subtotal/Partial gland prostate cryoablation: Results of 341 patients from multiple centers tracked with the cold registry. Presented AUA 2008, Orlando FL (2008), Abstract Number:08-AB-95484-AUAGoogle Scholar
  28. 28.
    Lavee, J., Onik, G., Mikus, P., Rubinsky, B.: A novel non-thermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg. Forum 10(2), E162–E167 (2007)CrossRefGoogle Scholar
  29. 29.
    Donnelly, B.J., Salikan, J.C., Ernst, D.S., et al.: Prospective trial of cryosurgical ablation of the prostate: Five year results. Urology 60(4), 645 (2002)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Gary Onik
    • 1
  • Boris Rubinsky
    • 2
    • 3
  1. 1.School of MedicineUniversity of Central FloridaOrlandoUSA
  2. 2.Department of Mechanical EngineeringUniversity of CaliforniaBerkeleyUSA
  3. 3.Center for Bioengineering in the Service of Humanity and Society, School of Computer Science and EngineeringHebrew University of JerusalemJerusalemIsrael

Personalised recommendations